Definium Therapeutics gets Breakthrough Therapy designation for DT120
Definium Therapeutics received Breakthrough Therapy designation for DT120 (lysergide) ODT in major depressive disorder after positive Phase 3 results.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.